Abstract -This review covers current developments in molecular-based studies of the structure and function of carboxylesterases. To allay the confusion of the classic classification of carboxylesterase isozymes, we have proposed a novel nomenclature and classification of mammalian carboxylesterases on the basis of molecular properties. In addition, mechanisms of regulation of gene expression of carboxylesterases by xenobiotics, and involvement of carboxylesterase in drug metabolism are also described.
INTRODUCTION
The mammalian carboxylesterases (CarbEs, EC 3.1.1.1) comprise a multi-gene family whose gene products are localized in the endoplasmic reticulum (ER) of many tissues of human and animals. These enzymes efficiently catalyze the hydrolysis of a variety of ester-and amide-containing chemicals as well as drugs and chemicals to the respective free acids. They are involved in detoxification or metabolic activation of various drugs, pesticides, environmental toxicants and carcinogens. CarbEs also catalyze the hydrolysis of endogenous compounds such as shortand long-chain acyl-glycerols, long-chain acyl-carnitine, and long-chain acyl-CoA esters (Mentlein et al., 1980; Hosokawa, 1990; Maki et al., 1991; Hosokawa and Satoh, 1996; Hosokawa et al., 2001; Furihata et al., 2004a; Furihata et al., 2004b; Furihata et al., 2005) . We have reviewed the characteristics of CarbEs in relation to the metabolism of xenobiotics Satoh and Hosokawa, 1998; Satoh and Hosokawa, 2006; Hosokawa et al., 2007) . Multiple isozymes of hepatic microsomal CarbE exist in various animal species (Hosokawa et al., 1987; Hosokawa et al., 1990; Hosokawa et al., 1994) , and some of these isozymes are involved in the metabolic activation of certain carcinogens, as well as being associated with hepatocarcinogenesis (Maki et al., 1991) .
Mammalian CarbEs are members of an α,β-hydrolase-fold family and are found in various mammalian species (Hosokawa, 1990; Kroetz et al., 1993; Brzezinski et al., 1994; Morgan et al., 1994; Yan et al., 1994; Yan et al., 1995a; Yan et al., 1995b; Yan et al., 1995c; Kusano et al., 1996; Brzezinski et al., 1997; Langmann et al., 1997a; Langmann et al., 1997b; Ellinghaus et al., 1998) . It has been suggested that CarbEs can be classified into five major groups denominated from CES1 to CES5, according to the homology of the amino acid sequence (Satoh and Hosokawa, 1998; Satoh and Hosokawa, 2006; Hosokawa et al., 2007) , and the majority of CarbEs that have been identified to belong to the CES1 or CES2 family.
It has also been shown that striking species differences exist Hosokawa et al., 1994; Prueksaritanont et al., 1996) . For example, Inoue et al. (Inoue et al., 1979a) showed that esterase activity in the dog intestine is very weak and produced no appreciable active band in a disk electrophoresis coupled with staining of esterase activity. On the other hand, esterase activities were observed in the intestines of other species (human, rat, mouse, guinea pig and rabbit) (Inoue et al., 1979b; Prueksaritanont et al., 1996; Mansbach and Nevin, 1998; Imai et al., 2006; Satoh and Hosokawa, 2006) and found to produce a few active bands in an electrophoretic assay.
It is thought that CarbEs are one of the major determi-family includes the major isoforms of rat, mouse and hamster CarbE, and CES1C includes the major isoforms of dog, cat and pig CarbE (Robbi and Beaufay, 1987; Ovnic et al., 1991b; Zschunke et al., 1991; Yan et al., 1995c; Hosokawa and Satoh, 1996; Potter et al., 1998; Mori et al., 1999; Hosokawa et al., 2001; Furihata et al., 2004a) . The CES 1H subfamily includes RL1 (CES1H4), mouse ES 4 (CES1H1) and hydrolase B (CES1H3) and C (CES1H2), which catalyze long-chain acyl-CoA hydrolysis (Hosokawa et al., 1987; Yan et al., 1994; Yan et al., 1995c; Hosokawa and Satoh, 1996; Robbi et al., 1996) . Members of the CES 1G family are not retained in ER, which are secreted to blood from liver (Ovnic et al., 1991b; Yan et al., 1995b) . These families are all secretary type CarbEs. It is interested that CES1G family are found in only rats and mice, but not in humans, and they are all a secretary type of CESs. Although high level of CES1 activity is detected in the blood of rats and mice, but no activity is detected in human blood.
In contrast, the CES2 family is mainly expressed in small intestine. It includes human intestinal CarbE (CES2A1) (Schwer et al., 1997; Humerickhouse et al., 2000; Imai et al., 2006; Taketani et al., 2007; Yang et al., 2007; Shi et al., 2008) , rCES2 (CES2A10) (Furihata et al., 2005) , rat intestinal CarbE RL4 (rCES2) (CES2A6) (Furihata et al., 2003) , rabbit form 2 (Ozols, 1989) and hamster AT51 (CES2A11) (Sone et al., 1994) . CES3 includes ES-male (CES3A2) and human CES3 (CES3A1) (Aida et al., 1993; Sanghani et al., 2004) . Human CES3 (CES3A1) has about 40% amino acid sequence identity with both CEA1A1 and CES2A1, and is expressed in the liver and gastrointestinal tract at an extremely low level in comparison with CES1A1 and CES2A1 (Sanghani et al., 2004) .
The CES4 family includes carboxylesterase-like urinary excreted protein (CAUXIN) (CES4A2), which is excreted as a major urinary protein in cat urine (Miyazaki et al., 2006a; Miyazaki et al., 2006b) . The CES 5 family includes 46.5-kDa CarbE isozymes (Probst et al., 1991) , which have a different structure from the structures of isozyme in other CarbE families. Esterase (ES) 46.5-kDa from mouse liver (Watanabe et al., 1993) and amide hydrolase of monkey liver (Kusano et al., 1996) probably belong to this family. These groupings are similar to the results of phylogenic analysis (Fig. 1) .
STRUCTURE AND CATALYTIC MECHANISM OF CarbE ISOZYMES
It has been shown that several proteins of the endoplasmic reticulum (ER) lumen have a common carboxy-termi- Fig. 1 . Phylogenic tree and nomenclature of CarbE families. CarbE isozymes are classified into five families, CES1, CES2, CES3, CES4 and CES5. Each family is also divided into subfamilies. nal sequence, KDEL-COOH, and that the structural motif is essential for retention of the protein in the luminal side of the ER through the KDEL receptor bound to the ER membrane (Pelham, 1990; Robbi and Beaufay, 1991; Tang and Kalow, 1995) . Korza and Ozols (Korza and Ozols, 1988) and Ozols (Ozols, 1989) established the primary structures of two microsomal esterases purified from rabbit liver and designated them 60-kDa esterase forms 1 and form 2, respectively. These two forms of CarbE have the consensus sequence for the ER retention tetra-peptide (HTEL or HIEL in the one-letter code) that is recognized with the luminal side of the KDEL receptor. The HXEL-COOH motif is also essential for retention of the protein in the luminal side of the ER through the KDEL receptor bound to ER membrane (Pelham, 1990; Robbi and Beaufay, 1991; Tang and Kalow, 1995) . Robbi et al. (Robbi et al., 1990) reported cDNA cloning of rat liver CES1B4 (ES-10). That was the first report to show that cDNA of liver CarbE has the consensus sequence of the ER retention tetrapeptide (HVEL-COOH).
Later, Robbi and Beaufay (Robbi and Beaufay, 1994 ) isolated a cDNA clone of another rat liver CES1D2 (ES-3, egasyn) which encoded the consensus sequence of the ER retention tetrapeptide (HTEL-COOH). The other clone encoded egasyn, an accessory protein of β-glucuronidase in the liver microsomes (Medda et al., 1987) . Egasyn is identical to CarbE, and it binds β-glucuronidase via its CarbE active site. In the case of rat and mouse, the carboxyl terminal amino acid sequence of clone rat CES- 60KDa (CES1G1) and mouse Es-N (CES1G2) is HTEHK-COOH, which can not bind to KDEL-receptor, and these isozymes are secreted to blood (Ovnic et al., 1991b) .
CarbEs have a signal peptide of 17 to 22 amino acid residues of N-terminal amino acid, including hydrophobic amino acid. In CES1 family, exon1 encodes a signal peptide (Ovnic et al., 1991a; Shibata et al., 1993) . In a case of CES1 family, a bulky aromatic residue (Trp) followed by a small neutral residue (Gly) directly precedes the cleavage site (von Heijne, 1983) . CarbEs have four Cys residues that may be involved in specific disulfide bonds. Among them, Cys98 is the most highly conserved residue in many CarbE isozymes. Cygler et al. (Cygler et al., 1993) reported an important alignment of a collection of related amino acid sequences of esterase, lipase and related proteins based on X-ray structures of Torpedo californicaAChE and Geotrichum candidum lipase.
According to literature, Ser203, Glu336 and His450 form a catalytic triad, and Gly124-Gly125 may be part of an oxyanion hole (Fig. 2) . These residues are also highly conserved among CarbE isozymes. Site-specific mutation of Ser203 to Thr203, Glu336 to Ala336, or His450 to Ala450 greatly reduced the CarbE activity towards substrates. Therefore, the mutagenesis confirmed a role of Glu 336 and His 450 in forming a putative charge relay system with active site Ser203 (Satoh and Hosokawa, 1998) . Frey et al. (1994) reported that the formation of low barrier hydrogen bonds between His and Asp (Glu for CarbE) facilitates nucleophilic attack by the β-OH group of Ser on the acyl carbonyl group of peptide in chymotrypsin. The catalytic triad in the tetrahedral addition intermediate is stabilized by the low barrier hydrogen bonds. According to their theory, we speculated that the low barrier hydrogen bond between Glu336 and His 450 facilitates nucleophilic attack by the β-OH group of Ser203 on the carbonyl group of the substrate in CarbE (Fig. 2) .
The mechanism of CarbE could thus be divided into next steps. 1) The enzyme substrate complex form, positioning the substrate in the correct orientation for reaction. 2) Hydrolysis of the ester bond starts with an attack by the oxygen atom of the hydroxy group of Ser203 on the carbonyl carbon atom of the ester bond.
3) The hydrogen bonds between the negatively charged oxygen of the tetrahedral intermediate and the N-H group of Gly123 and Gly124 stabi-lize the negatively charged oxygen (O − ). This configuration, in which negatively charged carboxyl oxygen is hydrogen bonded to two N-H group, is called oxyanion hole.
In the general acid-catalyzed step, the ester bond breaks, and the leaving group picks up a proton from the imidazolium ion of His450. The acyl portion of the original ester bond remains bound to the enzyme as an acyl-enzyme intermediate. The alcohol component (R'-OH) diffuses away, completing the acylation stage of the hydrolytic reaction. 4) A water molecule attacks the acyl-enzyme intermediate to give a second tetrahedral intermediate. 5) His450 then donates the proton to the oxygen atom of Ser203, which then releases the acid component of the substrate. The acid component diffuses away and the enzyme is ready for catalysis.
The tetrahedral transition state is stabilized by the formation of low barrier hydrogen bonds between His 450 and Glu336. The low barrier hydrogen bonds facilitated mechanism includes weak hydrogen bonds between the oxyanion (O − ) and peptide N-H bonds contributed by Gly 123 and Gly124, which stabilize the tetrahedral adduct on the substrate side of the transition state (Fig. 2) . Formation of the acyl-enzyme complex in the next step requires removal of a proton from His450, so that the tetrahedral intermediate is disrupted in the acyl-enzyme intermediate. When the unbound portion of the alcohol group of the first product of the substrate has diffused away, a second step which the deacylation step is essentially the reverse of the acylation step occurs, with a water molecule substituting for the alcohol group of the original substrate.
It is of interest that the sequences required for the hydrolytic capability at the catalytic triad (Glu, His, Ser) of CarbE, AChE, BuChE, and cholesterol esterase are highly conserved. This is a common structure of α,β-hydrolasefold families, which are responsible for the hydrolysis of endogenous and exogenous compounds. Furthermore, these elements are strongly conserved among orthologous CarbEs of the mouse, rat, rabbit, monkey and human.
A three-dimensional model for human CarbE has been proposed on the basis of crystal structure coordinates of AChE and overlapping active sites with pancreatic lipase and CarbE (Alam et al., 2002) . The modeled structure shares the overall folding and topology of the proteins identified in the recently published crystal structures of the rabbit (Bencharit et al., 2002) and human CarbE (Wong and Schotz, 2002; Bencharit et al., 2003a) . CarbE has a three-dimensional α,β-hydrolase-fold structure, which is a structural feature of all lipases (Wong and Schotz, 2002) . In general, the structure of CarbE may be viewed as comprising a central catalytic domain surrounded by α-β and regulatory domains (Bencharit et al., 2002; Bencharit et al., 2003a; Bencharit et al., 2003b) . In essence, the α,β-hydrolase-fold consists of a central β-sheet surrounded by a variable number of α-helices and accommodates a catalytic triad composed of Ser, His and a carboxylic acid. This suggests that the catalytic function of these proteins is conserved across species.
The catalytic triad is located at the bottom from about 25 Å deep active site, approximately in the center of the molecule and comprises a large flexible pocket on one side of Ser203 and a small rigid pocket on the opposite side (Bencharit et al., 2003a) . The orientation and location of the active site provide an ideal hydrophobic environment for the hydrolysis of a wide variety of hydrophobic substrates (Bencharit et al., 2003a) . The small rigid active site pocket is adjacent to the oxyanion hole formed by Gly [123] [124] and is lined by several hydrophobic residues (Bencharit et al., 2003a) .
Short acyl chains would be easily accommodated within the small rigid pocket. The larger flexible active site pocket is lined by several non-polar residues and could accommodate larger or polycyclic molecules such as cholesterol. The large pocket is adjacent to a side door secondary pore that would permit small molecules (substrates and reaction products) to enter and exit the active site (Bencharit et al., 2003a) . Longer acyl chains may be oriented for catalysis in such a way that they extend through the side door. Indeed, the presence of a hydrophobic residue at position 423 in mice CES1B2 and 425 in humans CES1A1 is necessary for efficient hydrolysis of hydrophobic substrates, as mutation of Met present in position 423 of the related rat lung CarbE (CES1B4) to Ile increased the CarbE activity towards a more hydrophobic substrate without affecting activity towards short-chain esters (Wallace et al., 1999) .
Most CarbE isozymes are glycol-proteins, and the carbohydrate chain is required for the enzyme activity of CarbEs (Hosokawa, 1990; Kroetz et al., 1993; Satoh and Hosokawa, 1998; Bencharit et al., 2003a; Imai, 2006; Hosokawa et al., 2007) . Human CES2A1 contains a glycosylation site at two different positions (Asn 103 and Asn 267 ), while CES1A1 contains only one glycosylation site at Asn79. This glycosylation site is modified by a carbohydrate chain with first N-acetylglucosamine and terminal sialic acid and appears to be involved in the stabilization of the CES1A1 trimer by packing into the adjacent monomer in its crystal structure (Bencharit et al., 2003a) .
According to the X-ray crystal structure of human CES1, this residue lines the flexible pocket adjacent to the side door (Bencharit et al., 2003a) . Given the wide range of substrates that CarbEs are known to hydrolyze, the large flexible pocket confers the ability to hydrolyze many structurally distinct compounds, whereas the rigid pocket is much more selective with regard to the substrates that may be accommodated.
GENE STRUCTURE AND REGULATION OF CarbE ISOZYMES
Both the murine (Hosokawa et al., 2007) and human (Shibata et al., 1993; Langmann et al., 1997b) CES1 genes span about 30 kb and contain 14 small exons. Recently, sequencing of the mouse and human genomes have been completed, enabling detailed sequence comparisons. Previously published sequences of individual exons, splice junctions, size of the introns and restriction sites within the murine and human CarbE genes are consistent with their respective genes sequenced by the mouse and human genome projects. Therefore, the organization of the CarbE gene is evolutionarily conserved in mice and humans. Previous studies have mapped the human CarbE gene to chromosome 16 at 16q13-q22.1 (Zschunke et al., 1991; Kroetz et al., 1993) . This region is syntenic to a region of mouse chromosome 8 at 8C5. The murine CarbE Es22 (Ovnic et al., 1991a) and Es-N (Ovnic et al., 1991b) have been previously mapped to chromosome 8. The completion of the mouse genome sequencing project unambiguously demonstrated that the murine CarbE gene was located on the minus strand of chromosome 8 at 8C5 in a cluster of six CarbE genes that spans 260.6 kb in total.
These six CarbE genes are presumed to be originated from repeated gene duplications of a common ancestral gene that encoded a CarbE (Shibata et al., 1993) , and subsequent evolutionary divergence may occur.
Recently, we have identified a mouse liver microsomal acylcarnitine hydrolase, mCES2, as a member of the CES 2 family (Furihata et al., 2003) . It has been revealed that this enzyme is significantly induced by di(2-ethylhexyl) phthalate (DEHP) and shows medium-and long-chain acylcarnitine hydrolase activity (Furihata et al., 2003) . In addition, we have found that mCES2 is expressed in various tissues with higher levels of expression in the liver, kidney and small intestine. It was shown that three transcription factors, specificity protein (Sp) 1, Sp3 and upstream stimulatory factor 1, could bind to the promoter region of the mCES2 gene, leading to a synergistic transactivation of the promoter (Furihata et al., 2004b) . Although this mechanism may explain the ubiquitous tissue expression profiles of mCES2, it is unlikely to contribute to the higher levels of mCES2 expression in the liver, kidney and small intestine.
Therefore, it is thought that there exists another mechanism controlling this tissue-specific transcription of the mCES2 gene (Furihata et al., 2004b) . More recently, we have shown that hepatocyte nuclear factor-4 alpha (HNF-4α) can strongly enhance mCES2 gene transcription and that the involvement of HNF-4α accounts for the high expression level of mCES2 in the liver (Furihata et al., 2006) . These findings are notable when physiological roles of mCES2 are studied, since HNF-4α is involved in various hepatic functions, such as glucose and cholesterol metabolism and drug metabolism. In addition, we found that bile acid can repress mCES2 gene transcription by repressing HNF-4α-mediated transactivation (Furihata et al., 2006) .
We have isolated and characterized two genes encoding the human CES1A1 (AB119997) and CES1A2 (AB119998), and we also cloned and sequenced the 5' flanking region of each gene in order to elucidate the structure of the promoter (Fig. 3) .
It is noteworthy that both the CES1A1 and CES1A2 genes are located on chromosome 16q13-q22 with a tail-to-tail structure. A comparison of the nucleotide sequences of CES1A1 and CES 1A2 genes revealed about 98% homology in 30 Kbp. There are only six nucleotide differences resulting in four amino acid differences in the open reading frame, and all of the differences exist in exon 1.
Gene duplication has generally been viewed as a necessary source of material for the origin of evolutionary novelties, and duplicate genes evolve new functions. The majority of gene duplicates are silenced within a few million years, with the small number of survivors subsequently being subjected to strong purifying selection. Although duplicate genes may only rarely evolve new functions, the stochastic silencing of such genes may play a significant role in the passive origin of new species. Since exon 1 of the CES1 gene encodes a signal peptide region, intracellular localization of the CES1 gene product was preliminary investigated using a signal peptide/EYFP-ER chimera protein-expressing system. It was interesting that the CES1A1 signal peptide/EYFP-ER chimera protein was localized to the endoplasmic reticulum, whereas the CES1A2 signal peptide/EYFP-ER chimera protein was distributed in the endoplasmic reticulum and cytosol.
On the other hand, CES1A2 mRNA was found to be expressed only in human adult liver, although CES1A1 is expressed in human adult liver and fetal liver . These results suggested that CES1A1 and CES1A2 have different intracellular localizations and different expression profiles in liver differentiation. We inves- 4 . CarbE-UGT interaction in the luminal side of the ER membrane and CarbE-transporter interaction in the cell. Two hydrolyzed products from ester-substrate are formed by CarbE; alcohol or phenol, which are substrates for UGT, and organic anions, which are substrates for organic anion transporter such as multidrug resistanceassociated protein 2 (MRP2) or breast cancer resistance protein (BCRP). tigated the transcriptional regulation of these two CarbE genes. Reporter gene assays and electrophoretic mobility shift assays demonstrated that Sp1 and C/EBPα could bind to each responsive element of the CES1A1 promoter but that Sp1 and C/EBP could not bind to the responsive element of the CES1A2 promoter (Fig. 4) .
More recently Fukami et al. (Fukami et al., 2008) reported that the sequences of downstream and upstream of intron of CES1A2 gene are identical with those of CES1A1 and CES1A3 genes, respectively. A CES1A1 variant of which exon 1 is converted with that of the CES1A3 gene (the transcript is CES1A2) has recently been identified. They find that the CES1A2 gene is a variant of the CES1A3 pseudogene (Fig. 3) . The expression level of CES1A1 mRNA is much higher than that of CES1A2 mRNA in the liver . Since CES1A1 is highly variable in the individual liver (Hosokawa et al., 
−: undetectable, ＋: weakly expressed, ＋＋: moderately expressed, ＋＋＋: strongly expressed, NT: not tested.
1995), it was thought that these results provide information on individual variation of human CES1. As shown in Table I , human CES1 and CES2 were highly expressed in liver and lung, and small intestine and kidney, respectively. Knowledge of these substrate structure-activity relationships and the tissue distribution of CarbE isozymes is critical for predicting the metabolism and the pharmacokinetics and pharamcodynamics of pesticides.
POSSIBLE ROLE OF CarbE ISOZYMES IN DRUG METABOLISM AND PHARMACOKINETICS

Drug metabolism
Drug metabolizing enzymes that are present predominantly in the liver are involved in biotransformation of both endogenous and exogenous compounds to polar products to facilitate their elimination. These reactions are categorized into phase 1 and phase 2 reactions.
CarbEs show ubiquitous tissue expression profiles with the highest levels of CarbE activity present in liver microsomes in many mammals (Mentlein et al., 1980; Hosokawa et al., 1984; Maki et al., 1991; Hattori et al., 1992; Hosokawa and Satoh, 1993; Watanabe et al., 1993; Hosokawa et al., 1995; Derbel et al., 1996; Lehner et al., 1999; Furihata et al., 2004a) . CarbEs are categorized as phase 1 drug metabolizing enzymes that can hydrolyze a variety of ester-containing drugs and prodrugs. These include angiotensin-converting enzyme (ACE) inhibitors (temocapril, cilazapril, quinapril, and imidapril) (Takai et al., 1997; Mori et al., 1999; Furihata et al., 2004a; Geshi et al., 2005) , anti-tumor drugs (CPT-11 and capecitabin) Danks et al., 1998; Guichard et al., 1998; Kojima et al., 1998; Humerickhouse et al., 2000; Sanghani et al., 2004; Tabata et al., 2004) , and narcotics (cocaine, heroin and meperidine) (Kamendulis et al., 1996; Zhang et al., 1999) . Thus, CarbEs are one of the most important enzymes involved in prodrug activation notably with respect to tissue distribution, up-regulation in tumor cells and turnover rates.
Recent studies have shown that there are some differences between these families in terms of substrate specificity, tissue distribution, immunological properties, and gene regulation (Hosokawa et al., 2007) . Analysis of substrate structure versus catalytic efficiency for the ester or carbamate substrates reveals that the different family of CarbEs recognizes different structural features of the substrate. For example, the preferential substrates for CES1A1, a human CES1 family isozyme, are thought to be compounds esterified by small alcohols, while those for CES2A1, a human CES2 family isozyme, are thought to be compounds esterified by relatively large alcohols. CES1A1, but not CES2A1, hydrolyzed the methyl ester of cocaine and the ethyl esters of temocapril, meperidine, imidapril and oseltamivir (Pindel et al., 1997; Takai et al., 1997; Mori et al., 1999; Satoh et al., 2002; Furihata et al., 2004a; Shi et al., 2006; Ose et al., 2009) .
It was interesting that procainamide inhibited the CES1 mediated imidapril hydrolysis (Takahashi et al., 2009) . Procainamide is also known as a choline binding pocket specific inhibitor (Jagnahtan and Boopathy, 1998) and has been reported to competitively inhibit human BuChE (Rush et al., 1981) . Takai et al. (1997) reported that the local anesthetic drug procaine and the anti-cholinergic drug oxybutynin with large alcohol substitutes are substrates for CES2 but not CES1. Procainamide is also a good substrate for CES2. Because the amino acid sequences at the active site were highly conserved among CES1, CES2 and BuChE , it is reasonable to assume that procainamide inhibits CES1-mediated imidapril hydrolysis.
In contrast to the specificity of CES1 for the methyl ester of cocaine, only CES2 hydrolyzed the benzoyl ester of cocaine (Pindel et al., 1997) . The benzoyl ester of cocaine, heroin and CPT-11 bearing a small acyl moiety and a bulky alcohol group are good substrates for the CES2 isozyme. It was interesting that BuChE hydrolyzed the benzoyl ester of cocaine, and also hydrolyzed CPT-11, but not AChE (Mattes et al., 1996; Lynch et al., 1997; Christopher et al., 1999) . CPT-11 is a relatively potent and selective inhibitor of human AChE that has properties of the acute cholinergic toxicity observed in some patients (Dodds and Rivory, 1999) .
It has been suggested that although these two CarbE families exhibit broad substrate specificity for ester, carbamate, or amide hydrolysis, these CarbE isozymes do exhibit distinct catalytic efficiencies that correlate with the relative size of the substrate substituents versus that of the enzyme active sites. Tissue specific expression of CES1 and CES2 was examined by northern blots, RT-PCR and real time PCR analysis.
Pharmacokinetics
It is thought that CarbEs are one of the major determinants for pharmacokinetics and pharmacodynamics of drugs and ester prodrugs (Fig. 4) . Actually, it has been shown that dog CES1 isozyme was involved in a pulmonary first-pass effect in the disposition of a propranolol ester prodrug (Imai, 2006; Imai et al., 2006) . It has also been shown that the expression level of the human CarbE isozyme was correlated with the conversion ratio of CPT-11 to SN-38, the active metabolite, which is thought to be a key step for the chemotherapeutic action of this anti-tumor drug (Pindel et al., 1997; Zhang et al., 2002; Ohtsuka et al., 2003; Sanghani et al., 2003) .
Since many drug metabolizing enzymes, such as cytochrome P450 (CYP), CarbE, UDP-glucuronosyltransferase (UGT) and sulfotransferase, and transporters, such as P-glycoprotein (P-GP), multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP), were co-expressed in liver and small intestine, the hydrolysis activity in the liver and small intestine is contribute to drug metabolism and drug transport with phase II drug metabolizing enzyme or drug transporter. The CarbEs and the UGT families, the catalytic domains of which are localized in the luminal sides of the endoplasmic reticulum (ER) membrane, are two major enzyme groups responsible for phase 1 and 2 reactions (Fig. 4) . The hydrolyzed products of CarbEs are also the substrate for UGT, such as SN-38 from CPT-11. Thus, we thought that CarbE-UGT interaction in the luminal sides of ER membrane is important for drug metabolism. Furthermore, hydrolyzed products of CarbEs consist of two kinds of chemical properties. One is the alcohol or phenol that are substrates for UGT, and the other is organic anions which are substrates for organic anion transporter such as multidrug resistance-associated protein 2 (MRP2) or BCRP. In this regard, we thought CarbEs are one of the major drug-metabolizing enzymes for enzyme-enzyme interaction or enzyme-transporter interaction.
GENETIC POLYMORPHISM
Geshi at al. first reported that a single nucleotide polymorphism (SNP), -816A/C of the CES1A2 gene associates with the responsiveness to an angiotensin-converting enzyme (ACE) inhibitor, imidapril, whose activity is achieved by CES1 isozyme (Geshi et al., 2005) . Recently we re-sequenced the CES1A2 promoter region (-1 kB) in 100 Japanese hypertensive patients. Altogether ten SNPs and one insertion/deletion (I/D) were identified, among which six SNPs and one I/D residing between −47 and −32 were in almost complete linkage disequilibrium (D'=1.00, r2=0.97) (Yoshimura et al., 2008) . They consisted of a minor and a major haplotype, the allele frequencies of which were 22% and 74%, respectively. The minor haplotype possessed two putative Sp1 binding sites while the major haplotype did not have any Sp1 binding site. The minor haplotype had a higher transcription and Sp1 binding activities than the major haplotype, in vitro.
More recently, we studied the relationship between CES1A1 polymorphisms and CES activity in forty-five human liver tissues (in preparation). Altogether, six single nucleotide polymorphisms (SNPs), −75G/T, −46A/G, −39A/G, −21C/G, −20G/A, −2G/C and one insertion/deletion (I/D), ＋71A/del were identified in the promoter region of CES1A1 gene. The ＋71 A/del was significantly associated with the efficacy of conversion of CPT-11 to SN38 and the level of immunoreactive CES1 protein in the liver microsomes. The ＋71 A/del was not associated with CES1A1 mRNA level in the liver, and an in vitro reporter assay indicated that ＋71A/del does not affect transcription. These results suggest that CES1A1 ＋71A/del may account at least in part for the inter-individual difference of CarbE activity in human liver microsomes. These polymorphism of CarbE genes may be a good candidate for studying pharmacogenetics for the detoxification of drugs and chemicals
CONCLUSIONS
Multiple CarbEs play an important role in the hydrolytic biotransformation of a vast number of structurally diverse drugs. These enzymes are major determinants of the pharmacokinetic behavior of most therapeutic agents containing an ester or amide bond. There are several factors that influence CarbE activity, either directly or at the level of enzyme regulation. In the clinical field, drug elimination is decreased and the incidence of drug-drug interactions increases when two or more drugs compete for hydrolysis by the same CarbE isozyme.
Exposure to chemicals or lipophilic drugs can result in induction of CarbE activity. Several drug-metabolizing enzymes, such as CYP, UGT and sulfotransferase have been extensively studied to clarify the substrate specificity using molecular cloning and cell expression systems. Consequently, the novel findings obtained reveal that the substrate specificity of CarbE is, at least in part, explained by the differences in the nucleotide sequences of the individual CarbE isozymes.
It is clear that membrane-bound type CarbE isozymes in microsomes are required to possess the KDEL tetrapeptide motif at the carboxy terminal of the molecule. Mammalian CarbEs have been found to have acyl glycerol, acyl-CoA, and acyl-carnitine hydrolyzing activities in vitro, however, physiological roles of CarbE remain unclear. To clarify the substrate specificity of each CarbE isozyme, we have begun to study for searching the substrate recognition site of each isozyme.
In the present review, we described the substrate specificity and tissue-specific expression profile of CarbE isozymes. Therefore, successful design of ester-containing drugs will be greatly improved by further detailed analysis for the mechanism of action and substrate recognition site of CarbE isozymes.
In conclusion, the molecular based information of CarbEs in this review must be useful to understand the multiplicity and substrate specificity of CarbE family associated with efficacy, side effects and toxicity of chemicals.
